Incannex Healthcare Ltd ADR (IXHL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Incannex Healthcare Ltd ADR stock (IXHL) is currently trading at $2.78. Incannex Healthcare Ltd ADR PS ratio (Price-to-Sales) is 7764.11. WallStSmart rates IXHL as Sell.
- IXHL PE ratio analysis and historical PE chart
- IXHL PS ratio (Price-to-Sales) history and trend
- IXHL intrinsic value — DCF, Graham Number, EPV models
- IXHL stock price prediction 2025 2026 2027 2028 2029 2030
- IXHL fair value vs current price
- IXHL insider transactions and insider buying
- Is IXHL undervalued or overvalued?
- Incannex Healthcare Ltd ADR financial analysis — revenue, earnings, cash flow
- IXHL Piotroski F-Score and Altman Z-Score
- IXHL analyst price target and Smart Rating
Incannex Healthcare Ltd ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Incannex Healthcare Ltd ADR (IXHL) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Incannex Healthcare Ltd ADR (IXHL) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Incannex Healthcare Ltd ADR (IXHL) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 7764.1x annual revenue
Very low institutional interest at 2.89%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Incannex Healthcare Ltd ADR (IXHL) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.57) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (7764.11) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -130.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -130.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IXHL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IXHL's Price-to-Sales ratio of 7764.11x sits near its historical average of 7764.11x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 7764.11x set in Mar 2026, and 0% above its historical low of 7764.11x in Mar 2026.
Compare IXHL with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Incannex Healthcare Ltd ADR (IXHL) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Incannex Healthcare Ltd ADR operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 69M in cash.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.68, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Incannex Healthcare Ltd ADR.
Bottom Line
Incannex Healthcare Ltd ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Incannex Healthcare Ltd ADR(IXHL)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Incannex Healthcare Limited is engaged in the research, development and sale of medicinal cannabinoid products in Australia. The company is headquartered in Sydney, Australia.